Rheumatoid Arthritis: An Overview of New and Emerging Therapies
Identifieur interne : 001E41 ( Main/Exploration ); précédent : 001E40; suivant : 001E42Rheumatoid Arthritis: An Overview of New and Emerging Therapies
Auteurs : Tanya Doan [États-Unis] ; Elena Massarotti [États-Unis]Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2005-07.
Abstract
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disorder characterized by symmetric inflammation of synovial joints leading to progressive erosion of cartilage and bone. The aim of treatment is to mitigate joint destruction, preserve function, and prevent disability. The American College of Rheumatology guidelines for the treatment of RA recommend that newly diagnosed patients with RA begin treatment with disease‐modifying antirheumatic drugs (DMARDs) within 3 months of diagnosis. Methotrexate remains the most commonly prescribed DMARD and is the standard by which recent new and emerging therapies are measured. Increasing knowledge regarding the immunologic basis of RA and advances in biotechnology have resulted in new, targeted biological therapies against proinflammatory cytokines that have dramatically changed the treatment paradigm and outcomes of patients with RA. This article reviews the pharmacological rationale underlying RA therapy, with a focus on currently available biological therapies and new therapies in development.
Url:
DOI: 10.1177/0091270005277938
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000111
- to stream Istex, to step Curation: 000111
- to stream Istex, to step Checkpoint: 000C91
- to stream Main, to step Merge: 001E55
- to stream Main, to step Curation: 001E41
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rheumatoid Arthritis: An Overview of New and Emerging Therapies</title><author><name sortKey="Doan, Tanya" sort="Doan, Tanya" uniqKey="Doan T" first="Tanya" last="Doan">Tanya Doan</name></author><author><name sortKey="Massarotti, Elena" sort="Massarotti, Elena" uniqKey="Massarotti E" first="Elena" last="Massarotti">Elena Massarotti</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2A68851DCD7ADCD3B525C32EF03F1D2BE0A6C71D</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1177/0091270005277938</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-8W5WQZXD-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000111</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000111</idno><idno type="wicri:Area/Istex/Curation">000111</idno><idno type="wicri:Area/Istex/Checkpoint">000C91</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C91</idno><idno type="wicri:doubleKey">0091-2700:2005:Doan T:rheumatoid:arthritis:an</idno><idno type="wicri:Area/Main/Merge">001E55</idno><idno type="wicri:Area/Main/Curation">001E41</idno><idno type="wicri:Area/Main/Exploration">001E41</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Rheumatoid Arthritis: An Overview of New and Emerging Therapies</title><author><name sortKey="Doan, Tanya" sort="Doan, Tanya" uniqKey="Doan T" first="Tanya" last="Doan">Tanya Doan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Tufts—New England Medical Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Massarotti, Elena" sort="Massarotti, Elena" uniqKey="Massarotti E" first="Elena" last="Massarotti">Elena Massarotti</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Tufts—New England Medical Center, Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Correspondence address: Address for reprints: Elena Massarotti, MD, 750 Washington Street, NEMC 599, Boston</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Journal of Clinical Pharmacology</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACOLOGY</title><idno type="ISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><imprint><biblScope unit="vol">45</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="751">751</biblScope><biblScope unit="page" to="762">762</biblScope><biblScope unit="page-count">12</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2005-07">2005-07</date></imprint><idno type="ISSN">0091-2700</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-2700</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disorder characterized by symmetric inflammation of synovial joints leading to progressive erosion of cartilage and bone. The aim of treatment is to mitigate joint destruction, preserve function, and prevent disability. The American College of Rheumatology guidelines for the treatment of RA recommend that newly diagnosed patients with RA begin treatment with disease‐modifying antirheumatic drugs (DMARDs) within 3 months of diagnosis. Methotrexate remains the most commonly prescribed DMARD and is the standard by which recent new and emerging therapies are measured. Increasing knowledge regarding the immunologic basis of RA and advances in biotechnology have resulted in new, targeted biological therapies against proinflammatory cytokines that have dramatically changed the treatment paradigm and outcomes of patients with RA. This article reviews the pharmacological rationale underlying RA therapy, with a focus on currently available biological therapies and new therapies in development.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Doan, Tanya" sort="Doan, Tanya" uniqKey="Doan T" first="Tanya" last="Doan">Tanya Doan</name></region><name sortKey="Massarotti, Elena" sort="Massarotti, Elena" uniqKey="Massarotti E" first="Elena" last="Massarotti">Elena Massarotti</name><name sortKey="Massarotti, Elena" sort="Massarotti, Elena" uniqKey="Massarotti E" first="Elena" last="Massarotti">Elena Massarotti</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E41 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E41 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2A68851DCD7ADCD3B525C32EF03F1D2BE0A6C71D
|texte= Rheumatoid Arthritis: An Overview of New and Emerging Therapies
}}
| This area was generated with Dilib version V0.6.33. |  |